Toronto, Ontario and London, United Kingdom--(Newsfile Corp. - September 6, 2024) - Britannia Life Sciences Inc. (CSE: BLAB) (FSE: L020) (“Britannia” or the “Company”) is pleased to announce that on September 4, 2024, the Ontario Securities Commission (the “OSC”), the Company’s principal regulator, issued an order revoking the failure-to-file cease trade order that it imposed against the Company on August 2, 2024 (the “CTO”). The CTO was imposed following the Company’s failure to file its audited annual financial statements and related annual management’s discussion and analysis for the financial year ended March 31, 2024, and related certifications of such filings by the Company’s chief executive officer and chief financial officer, (collectively, the “Annual Filings”) as required by July 29, 2024.
The revocation order comes following the Company’s filing of the Annual Filings, as further described in the Company’s news release dated September 2, 2024, which are available for review under the Company’s profile on SEDAR+ (www.sedarplus.ca). Following the filing of the Annual Filings, the Company is up to date with its continuous disclosure obligations, and the Company is applying to the Canadian Securities Exchange (the “CSE”) for the resumption of trading of the Company’s common shares effective immediately.
About Britannia Life Sciences Inc.
Britannia Life Sciences Inc. is focused on introducing cutting-edge technologies into the traditional laboratory and regulatory platforms to power data-driven insights to improve the outcomes of its customers. Britannia’s services, including product formulations, safety assessments, analytical and microbiological testing, global compliance, and consumer evaluations are offered to companies ranging from multinationals to startups particularly in the cosmetics, food, and wellness industries. Britannia also provides geochemical testing and analysis to the natural resources industry through its subsidiary Britannia Mining Solutions. Britannia Mining Solutions operates a geochemical laboratory in the United States and is in the process of rolling out 12 PhotonAssayTM machines globally, the first two of which have been installed and commissioned to-date.
Britannia’s head office is located at 120 Adelaide Street West, Suite 2400, Toronto, Ontario, M5H 1T1.
For further information contact:
Britannia Life Sciences Inc.
Email: investors@britannia.life
Forward-Looking Information
This news release may contain certain “forward-looking information” and “forward-looking statements” (collectively, “forward-looking statements”) within the meaning of applicable Canadian securities legislation regarding Britannia and its business including, but not limited to, the delay in making its Annual Filings, the PhotonAssayTM being adopted by the world’s largest and most respected mining companies; PhotonAssayTM becoming the future industry benchmark for mineral analysis; and the Company’s ability to deploy additional PhotonAssayTM units worldwide over the next year. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates”, or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes”, or intends”, or variations of such words and phrases or stating that certain actions, events or results “may”, or “could”, “would”, “might”, or “will”, be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Except as required by law, Britannia assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change. The reader is cautioned not to place undue reliance on forward-looking statements.
For a detailed description of the risks and uncertainties facing the Company and its business and affairs, readers should refer to the Company’s most recet management discussion and analysis and annual financial statements, copies of which are available on SEDAR+ under the Company’s profile at www.sedarplus.ca.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/222482
